Literature DB >> 30248624

CAN anterior cervical fusion procedures prevent the progression of the natural course of Hirayama disease? An ambispective cohort analysis.

Chaojun Zheng1, Cong Nie1, Wei Lei1, Yu Zhu2, Dongqing Zhu3, Hongli Wang1, Feizhou Lu4, Robert Weber2, Jianyuan Jiang5.   

Abstract

OBJECTIVE: To clarify the effectiveness of anterior cervical fusion (ACF) in the treatment of Hirayama disease (HD).
METHODS: Sixty-nine HD patients who accepted ACF procedures underwent dynamic F-waves before and soon after operation, and 36 of the 69 patients underwent pre- and postoperative magnetic resonance imaging (MRI). Motor unit number estimation, handgrip strength (HGS) and disabilities of arm, shoulder and hand (DASH) were performed in these 36 HD patients and in the other 24 patients who accepted neither neck-collar support nor operation, and these tests were reassessed about one year after initial test.
RESULTS: Postoperatively, dynamic F-wave abnormalities were observed in fewer HD cases (2/69 vs. 25/69), and neck-flexion MRI abnormalities decreased significantly (P < 0.05). Compared with motor unit loss in patients who were untreated, follow-up analysis demonstrated no differences in motor unit, HGS or DASH in HD patients who underwent operation (P > 0.05), and mild recovery of motor units was observed in patients with preoperative abnormal dynamic F-waves (P < 0.05).
CONCLUSIONS: ACF procedures can immediately remove neck-flexion abnormalities and prevent or delay the progression of HD. SIGNIFICANCE: ACF procedures may provide effective, reliable and alternative methods for the treatment of HD, especially in HD patients with functional evidence of neck-flexion abnormalities.
Copyright © 2018 International Federation of Clinical Neurophysiology. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Anterior cervical fusion; Dynamic F-wave; Hirayama disease; Motor unit number estimation; Surgical treatment

Mesh:

Year:  2018        PMID: 30248624     DOI: 10.1016/j.clinph.2018.08.024

Source DB:  PubMed          Journal:  Clin Neurophysiol        ISSN: 1388-2457            Impact factor:   3.708


  6 in total

1.  The evaluation on neural status of cervical spinal cord in normal and Hirayama disease using diffusion tensor imaging.

Authors:  Chi Sun; Shuyi Zhou; Zhongyi Cui; Yuxuan Zhang; Hongli Wang; Jianyuan Jiang; Feizhou Lu; Xiaosheng Ma
Journal:  Eur Spine J       Date:  2019-05-20       Impact factor: 3.134

Review 2.  Impact of various cervical surgical interventions in patients with Hirayama's disease-a narrative review and meta-analysis.

Authors:  Sandeep Bohara; Kanwaljeet Garg; Shashwat Mishra; Vivek Tandon; P Sarat Chandra; Shashank Sharad Kale
Journal:  Neurosurg Rev       Date:  2021-04-21       Impact factor: 3.042

Review 3.  Juvenile muscular atrophy of the distal upper extremity (Hirayama syndrome): a systematic review.

Authors:  Henrik C Bäcker; Jacob Bock; Peter Turner; Michael A Johnson; John Cunningham; Patrick Chan; Richard Gerraty
Journal:  Eur Spine J       Date:  2022-06-21       Impact factor: 3.134

4.  Interobserver and Intraobserver Reproducibility and Reliability of the Huashan Clinical Classification System for Hirayama Disease.

Authors:  Chi Sun; Guangyu Xu; Yuxuan Zhang; Zhongyi Cui; Dayong Liu; Yong Yang; Xiandi Wang; Xiaosheng Ma; Feizhou Lu; Jianyuan Jiang; Hongli Wang
Journal:  Front Neurol       Date:  2021-12-03       Impact factor: 4.003

Review 5.  Update on the Pathogenesis, Clinical Diagnosis, and Treatment of Hirayama Disease.

Authors:  Hongwei Wang; Ye Tian; Jianwei Wu; Sushan Luo; Chaojun Zheng; Chi Sun; Cong Nie; Xinlei Xia; Xiaosheng Ma; Feizhou Lyu; Jianyuan Jiang; Hongli Wang
Journal:  Front Neurol       Date:  2022-02-01       Impact factor: 4.003

6.  Can preoperative cervical spinal diffusion tensor imaging (DTI) indices predict surgical outcomes in patients with Hirayama disease? A retrospective cohort study.

Authors:  Yuan Gao; Chi Sun; Shuyi Zhou; Xiaosheng Ma; Xinlei Xia; Feizhou Lu; Jun Zhang; Hongli Wang; Jianyuan Jiang
Journal:  Front Neurol       Date:  2022-09-30       Impact factor: 4.086

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.